TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Participants must provide documentation showing a sustained virologic response (SVR) for at least 1 year (52 weeks) prior to the date of screening (SVR is defined as a negative hepatitis C RNA greater than or equal to 12 weeks from the end of therapy)~* Participants must have METAVIR Stage 3 or 4 (or equivalent if using other classification; eg, Ishak)~Exclusion Criteria:~* Other causes of liver disease (eg, alcoholic liver disease, HBV \[serologically positive as determined using United States Centers for Disease Control and Prevention guidance for interpretation of hepatitis B serologic test results\], autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, NASH, hemochromatosis)~* Participants having liver diseases associated with infection with any other hepatitis virus~* Detectable HCV RNA at screening~* Child-Pugh score \> 6~* Model for End-Stage Liver Disease score \>12~* Evidence of HCC at screening based on alpha-fetoprotein (AFP) levels: AFP \> 100 ng/mL (\> 82.6 IU/mL) OR AFP ≥ 50 and ≤ 100 ng/mL (≥ 41.3 IU/mL and ≤ 82.6 IU/ mL) with liver ultrasound showing findings suspicious for HCC, or any imaging technique (eg, magnetic resonance imaging \[MRI\] or computed tomography; based on local assessment), or ultrasound~* Blood transfusion in the last 6 months prior to screening due to the risk of re-infection with HCV, HBV, HIV, etc~* Participant has any disease or condition which, in the opinion of the investigator, might compromise patient safety (eg, hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, central nervous system, or compliment-mediated disease); or other conditions that may interfere with the absorption, distribution, metabolism, or excretion of BMS 986263, or would place the participant at increased risk~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 BMS-986263 45mg weekly (Type: EXPERIMENTAL): None
- Part 1 BMS-986263 90mg weekly (Type: EXPERIMENTAL): None
- Part 1 Placebo weekly (Type: PLACEBO_COMPARATOR): None
- Part 2 BMS-986263 45mg every 2 weeks (Type: EXPERIMENTAL): None
- Part 2 BMS-986263 90mg every 2 weeks (Type: EXPERIMENTAL): None
- Part 2 BMS-986263 90mg every 4 weeks (Type: EXPERIMENTAL): None
- Part 2 Placebo every 2 weeks (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female on stable dose of IgPro20 (Hizentra) therapy.~* Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening.~* Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or X-linked agammaglobulinemia, as defined by the Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies.~* With infusion parameters as specified below:~Pump-Assisted Flow Rate Cohort subjects only~* Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25 mL/h per injection site for at least 1 month prior to Day 1.~Pump-Assisted Volume Cohort subjects only~* Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g).~* Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25 mL/injection site for at least 1 month prior to Day 1.~Manual Push Flow Rate Cohort subjects only~* Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site for at least 1 month prior to Day 1. The dose (volume) per injection site should not exceed 25 mL.~Exclusion Criteria:~* Ongoing serious bacterial infections at the time of screening.~* Other significant medical conditions that could increase the risk to the subject.~* Females who are pregnant, breast feeding, or planning a pregnancy during the course study.~* Participation in a study with an Investigational Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Pump-Assisted Volume Cohort) (Type: EXPERIMENTAL): Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
- IgPro20 (Pump Assisted Flow Rate Cohort) (Type: EXPERIMENTAL): Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
- IgPro20 (Manual Push Flow Rate Cohort) (Type: EXPERIMENTAL): Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Stable treatment with Oral Anti-Diabetic Drugs (metformin, sulphonylurea or a combination of both) for at least 3 months at the discretion of the Investigator~* HbA1C equal to or greater than 7.0% and equal to or lower than 11.0%~* Body Mass Index (BMI) equal to or lower than 45.0 kg/m2~Exclusion Criteria:~* Previous treatment with insulin~* Treatment with any anti-diabetic drug other than metformin and sulphonylurea~* Any previous exposure to exenatide or liraglutide~* Impaired liver or/and renal function~* History of any significant cardiac events~* Known retinopathy or maculopathy requiring acute treatment~* Recurrent major hypoglycaemia or hypoglycaemic unawareness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide 1.8 mg once daily + subject's own OAD treatment
- Exenatide (Type: ACTIVE_COMPARATOR): Exenatide 10 mcg twice daily + subject's own OAD treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: danceSing Care Evaluation: Testing the Effectiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* residents in care homes ≥ 65 years,~* able to complete 12 weeks of a movement and music program,~* having the capacity to give informed consent as assessed by care staff and confirmed in discussion about the project with the research team using the British Psychological Society capacity checklist~Exclusion Criteria:~* currently taking part in any other clinical trial which could potentially have an impact upon or influence the findings of the current study,~* pre-existing conditions or concurrent diagnoses which would profoundly impact their capacity to undergo the intervention, even once adaptations have been made,~* inability to adequately understand written/spoken English to participate in the measures and intervention (e.g., due to cognitive or sensory impairment).

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention group (Type: EXPERIMENTAL): The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of two movement sessions and one music session each week, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
- Waitlist control group (Type: NO_INTERVENTION): Waitlist for 12 weeks before participating in the digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be of legal age~* Having suffered from primary breast cancer with histological confirmation (I-IIIA)~* Completion of primary carcinoma treatment (surgery, chemotherapy, radiotherapy)~* To be receiving hormone therapy as an adjunct to the process by aromatase inhibitors (exemestane, anastrozole, letrozole)~* To present a functional status according to WHO from 0 (asymptomatic, complete and ambulatory activity) or 1 (symptomatic but completely ambulatory, strenuous physical activity restricted but able to perform sedentary gentle activities)~* To understand correctly Spanish~* To show their approval by signing the informed consent~* Having had musculoskeletal disorders attributable to IA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neuromuscular taping (Type: EXPERIMENTAL): The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
- No Kinesio taping (Type: NO_INTERVENTION): No Kinesio taping

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Type 2 diabetes~* BMI 30-49 kg/m²~* HbA1c ≥ 6.5% (48 mmol/mol)~* Appropriate life style intervention measures have been tried but have failed to achieve or maintain adequate, clinically beneficial weight loss for at least 6 months~* Person is generally fit for intervention~* Person commits to the need for long-term follow-up~Exclusion Criteria:~* Type 1 diabetes mellitus~* Maturity Onset Diabetes of the Young (MODY)~* Secondary diabetes due to a specific disease or glucocorticoid therapy~* Pregnancy or women of childbearing age without adequate contraception~* Women who are breast-feeding~* Hypothalamic cause of obesity, Cushing syndrome~* Major psychiatric disease including diagnosed eating disorders, history of drug or alcohol abuse~* History of bariatric surgery or complex abdominal surgery~* Inflammatory bowel disease~* Pancreatitis~* Cholelithiasis~* Uncontrolled gastroesophageal reflux~* Known upper GI bleeding conditions, e.g. gastric or esophageal varices~* Congenital or acquired abnormalities of the upper GI tract, e.g. stenosis~* Subjects with or a history of coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia~* Chronic non-steroidal anti-inflammatory drug (NSAID) or aspirin treatment (Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period)~* Previous GI surgery that could affect the ability to place the device or the function of the implant~* GLP-1 receptor agonist therapy~* Known ischaemic heart disease or heart failure~* History of stroke~* Active Helicobacter pylori (Note: Subjects may be enrolled if they had a prior history of Helicobacter Pylori and were successfully treated)~* Iron deficiency and/or iron deficiency anemia~* Subjects or Family history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder~* Known malignancy or any other multimorbid patient condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol or would put the participant at an unjustified risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EndoBarrier (Type: EXPERIMENTAL): EndoBarrier will be implemented for 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed unresectable AJCC stage III or stage IV melanoma~* Patients must have metastatic melanoma with a resectable metastatic lesion(s) of sufficient size (≥ 2-3 cm in total) and must be willing to undergo such a resection for experimental purposes.~* Patients should have received maximum one line of systemic therapy (except for ipilimumab) for unresectable or metastatic melanoma.\[~* Patients must be ≥ 18 years and ≤ 75 years of age and must have measurable disease by CT or MRI per RECIST 1.1 criteria (in addition to the resected lesion).~* Patients must have a clinical performance status of ECOG 0 or 1.~* Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for four months after receiving the preparative regimen.~* Patients must be able to understand and sign the Informed Consent document.~Exclusion Criteria:~* Life expectancy of less than three months.~* Patients with metastatic ocular/ mucosal or other non-cutaneous melanoma.~* Adjuvant treatment with ipilimumab within 6 months prior to randomization.~* Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to randomization.~* Patients who have a more than two CNS metastases.~* Patients who have any CNS lesion that is symptomatic, greater than 1 cm in diameter or show significant surrounding edema on MRI scan will not be eligible until they have been treated and demonstrated no clinical or radiologic CNS progression for at least 2 months.~* All patients' toxicities due to prior non-systemic treatment must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures or focal palliative radiotherapy (to non-target lesions) within the past 4 weeks, as long as all toxicities have recovered to grade 1 or less.~* Women who are pregnant or breastfeeding, because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.~* Any active systemic infections, coagulation disorders or other active major medical illnesses.~* Any autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: ACTIVE_COMPARATOR): 4 cycles of ipilimumab treatment, the standard treatment
- TIL treatment (Type: EXPERIMENTAL): non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reasonably healthy men and women aged 50 to 75~Exclusion Criteria:~* History of abnormal bleeding, active bleeding or risk factors for bleeding~* History of thrombosis or risk factors for thrombosis~* History of adult asthma or use of inhaled medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Andexanet 800mg bolus (Part I) (Type: EXPERIMENTAL): Andexanet (antidote) - 800 mg bolus
- Andexanet 800mg + 960mg (Part II) (Type: EXPERIMENTAL): 800 mg bolus + 960 mg infusion (8 mg/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is male and aged \>18 years old.~2. History of localized adenocarcinoma of the prostate with prior curative intent treatment.~3. An elevated PSA, clinically suspicious for biochemically recurrent disease:~   * Following Radical Prostatectomy: PSA \>0.2 ng/mL~  * Following Radiotherapy: nadir +2 ng/mL.~4. Potentially eligible for salvage therapy with curative intent.~Exclusion Criteria:~1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer \<24 hours prior to the PET scan.~2. Patients currently receiving Androgen Deprivation Therapy (ADT).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: EXPERIMENTAL): Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Monochromatic Light on Incidence of Emergence Delirium in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist Classification of 1,2~* Patients ages 2-6 years~* Routine tonsillectomy and adenoidectomy~Exclusion Criteria:~American Society of Anesthesiology classification other than 1,2; history of migraine headaches; ocular disorders; seizure history; psychiatric conditions; anxiety; parental refusal; developmental delay; patients on medication for attention deficit disorders or caffeine stimulants; Patients with contraindications to receiving inhalation agents; Use of premedication with midazolam or dexmedetomidine;

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Blue light - non monochromatic (Type: SHAM_COMPARATOR): None
- Monochromatic blue light (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Patient has had diagnosis of plaque-type psoriasis for at least 24 weeks.~Exclusion Criteria:~* Patients diagnosed with forms of psoriasis other than plaque-type.~* Patients previously received ustekinumab or a biosimilar of ustekinumab.~* Patient who has allergies to the active substance or any of the excipients of ustekinumab or study drug, or patients with a hypersensitivity to immunoglobulin products or natural rubber and latex.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CT-P43 (Type: EXPERIMENTAL): All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.
- Stelara (Type: ACTIVE_COMPARATOR): Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete